Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:ranibizumab-nuna
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
S01LA05
|
| gptkbp:biosimilar |
gptkb:Lucentis
|
| gptkbp:countryOfOperation |
gptkb:European_Union
gptkb:United_States |
| gptkbp:form |
solution for injection
|
| https://www.w3.org/2000/01/rdf-schema#label |
Byooviz
|
| gptkbp:indication |
retinal diseases
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Samsung_Bioepis
|
| gptkbp:marketedAs |
gptkb:Biogen
|
| gptkbp:routeOfAdministration |
intravitreal injection
|
| gptkbp:type |
biosimilar
|
| gptkbp:usedFor |
gptkb:neovascular_(wet)_age-related_macular_degeneration
macular edema following retinal vein occlusion myopic choroidal neovascularization |
| gptkbp:bfsParent |
gptkb:Lucentis
|
| gptkbp:bfsLayer |
5
|